Our top pick for
TransEnterix, Inc is a medical devices business based in the US. TransEnterix shares (TRXC) are listed on the NYSE MKT and all prices are listed in US Dollars. TransEnterix employs 160 staff and has a trailing 12-month revenue of around USD$2.8 million.
Since the stock market crash in March caused by coronavirus, TransEnterix's share price has had significant negative movement.
Its last market close was USD$0.42, which is 65.29% down on its pre-crash value of USD$1.21 and 50.00% up on the lowest point reached during the March crash when the shares fell as low as USD$0.28.
If you had bought USD$1,000 worth of TransEnterix shares at the start of February 2020, those shares would have been worth USD$246.03 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$333.33.
|Latest market close||USD$0.42|
|52-week range||USD$0.28 - USD$2.9055|
|50-day moving average||USD$0.4006|
|200-day moving average||USD$0.43|
|Wall St. target price||USD$1.45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.338|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||N/A|
|1 month (2020-10-30)||16.67%|
|3 months (2020-08-26)||N/A|
|6 months (2020-05-26)||N/A|
|1 year (2019-11-26)||N/A|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$2.8 million|
|Gross profit TTM||USD$-4,792,000|
|Return on assets TTM||-44.58%|
|Return on equity TTM||-94.1%|
|Market capitalisation||USD$43 million|
TTM: trailing 12 months
There are currently 5.1 million TransEnterix shares held short by investors – that's known as TransEnterix's "short interest". This figure is 20% up from 4.3 million last month.
There are a few different ways that this level of interest in shorting TransEnterix shares can be evaluated.
TransEnterix's "short interest ratio" (SIR) is the quantity of TransEnterix shares currently shorted divided by the average quantity of TransEnterix shares traded daily (recently around 2.3 million). TransEnterix's SIR currently stands at 2.24. In other words for every 100,000 TransEnterix shares traded daily on the market, roughly 2240 shares are currently held short.
However TransEnterix's short interest can also be evaluated against the total number of TransEnterix shares, or, against the total number of tradable TransEnterix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TransEnterix's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 TransEnterix shares in existence, roughly 50 shares are currently held short) or 0.0516% of the tradable shares (for every 100,000 tradable TransEnterix shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TransEnterix.
Find out more about how you can short TransEnterix stock.
We're not expecting TransEnterix to pay a dividend over the next 12 months.
TransEnterix's shares were split on a 1:13 basis on 12 December 2019. So if you had owned 13 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TransEnterix shares – just the quantity. However, indirectly, the new 1200% higher share price could have impacted the market appetite for TransEnterix shares which in turn could have impacted TransEnterix's share price.
Over the last 12 months, TransEnterix's shares have ranged in value from as little as $0.28 up to $2.9055. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while TransEnterix's is 2.4216. This would suggest that TransEnterix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company's products include Senhance System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and other select countries. The company was founded in 2006 and is based in Morrisville, North Carolina.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.